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BACKGROUND: American Indians/Alaskan Natives (AI/ANs) have the worst 5-year cancer survival of all racial/ethnic groups in the
United States. Causes for this disparity are unknown. The authors of this report examined the receipt of cancer treatment among AI/
AN patients compared with white patients. METHODS: This was a retrospective cohort study of 338,204 patients who were diag-
nosed at age 65 years with breast, colon, lung, or prostate cancer between 1996 and 2005 in the Surveillance, Epidemiology, and
End Results-Medicare database. Nationally accepted guidelines for surgical and adjuvant therapy and surveillance were selected as
metrics of optimal, guideline-concordant care. Treatment analyses compared AI/ANs with matched whites. RESULTS: Across cancer
types, AI/ANs were less likely to receive optimal cancer treatment and were less likely to undergo surgery (P.025 for all cancers).
Adjuvant therapy rates were significantly lower for AI/AN patients with breast cancer (P< .001) and colon cancer (P5.001). Rates of
post-treatment surveillance also were lower among AI/ANs and were statistically significantly lower for AI/AN patients with breast
cancer (P5.002) and prostate cancer (P<.001). Nonreceipt of optimal cancer treatment was associated with significantly worse sur-
vival across cancer types. Disease-specific survival for those who did not undergo surgery was significantly lower for patients with
breast cancer (hazard ratio [HR], 0.62), colon cancer (HR, 0.74), prostate cancer (HR, 0.52), and lung cancer (HR, 0.36). Survival rates
also were significantly lower for those patients who did not receive adjuvant therapy for breast cancer (HR, 0.56), colon cancer (HR,
0.59), or prostate cancer (HR, 0.81; all 95% confidence intervals were <1.0). CONCLUSIONS: Fewer AI/AN patients than white patients
received guideline-concordant cancer treatment across the 4 most common cancers. Efforts to explain these differences are critical
to improving cancer care and survival for AI/AN patients. Cancer 2014;120:2183–90. VC 2014 American Cancer Society.
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INTRODUCTION
American Indian/Alaskan Native (AI/AN) patients with cancer tend to present at more advanced stages of cancer and ex-
hibit the worst 5-year cancer survival of all racial/ethnic groups in the United States.1 The Centers for Disease Control
and Prevention’s analysis of cancer death rates from 1975 to 2004 demonstrated declining cancer death rates for all racial/
ethnic groups except for AI/ANs.2 Previous research on AI/AN patients with cancer is limited, because this group has
largely been evaluated only as part of a broader minority cohort. Therefore, factors underlying the lower cancer survival
rates of AI/ANs have not been well explained.
Worse survival among AI/ANs may stem from nonreceipt of recommended cancer treatments. A previous study that
assessed concordance with cancer treatment guidelines among Medicare beneficiaries indicated that receipt of guideline-
concordant cancer care varied depending on patient age, race, cancer type, and geographic region.3 Accepted practice
guidelines for most cancers are regularly updated by the National Comprehensive Cancer Network (NCCN), the
National Quality Forum (NQF), and the National Cancer Institute (NCI). In this study, our group, the Collaborative to
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Improve Native Cancer Outcomes (CINCO) identified
22 nationally endorsed practice guidelines for the 4 most
common cancers (breast, colon, prostate, and lung).
We used the Surveillance, Epidemiology, and
End Results (SEER)–Medicare-linked registry, a
population-based cancer data set that collects data on
all incident cancer cases in various areas across the
United States, capturing nearly 26% of the US pop-
ulation, including 42% of the AI/AN population.4
Although the AI/AN population represented in SEER
is concentrated in New Mexico, the Pacific North-
west, and California, the SEER data set offers the
most comprehensive examination of cancer incidence
and treatment in AI/AN populations across the
United States.5,6 Another benefit of the SEER-
Medicare data set is its linkage to Indian Health
Service (HIS) beneficiary records, which help to opti-
mize the correct race classification of AI/ANs.7
We hypothesized that AI/AN patients would be less
likely to receive optimal (or guideline-concordant) surgical
and adjuvant cancer treatment and were less likely to
undergo recommended post-therapy surveillance. We also
hypothesized that nonreceipt of optimal care would be
associated with worse survival. To test these hypotheses, we
assessed rates of adherence to each guideline for eligible AI/
AN patients and white patients. Our objective was to deter-
mine whether disparities exist in the receipt of guideline-
concordant treatment for 4 major cancers among AI/AN
patients. In addition, we examined the association between
receipt of optimal cancer care and disease-specific survival.
MATERIALS AND METHODS
Data Source
We used the National Cancer Institute (NCI) SEER can-
cer registry linked to Medicare enrollment and claims
TABLE 1. Definitions of Optimal Treatment
Metric Definition
Breast cancer
Metric 1 Axillary lymph node evaluation (sentinel lymph node biopsy or axillary dissection) for patients with stage 1-3 cancer who underwent any
breast surgeries (breast conserving or mastectomy) within 12 mo after diagnosis (National Comprehensive Cancer Network [NCCN] 3.2013,
BINV-D)
Metric 2a Receipt of radiation (RT) after breast-conserving surgery for stage 1-3 invasive breast cancer (excluding patients who underwent mastectomy
within 6 m after breast-conserving surgery; NQF 0219; NCCN 3.2013)
Metric 2b Receipt of chemotherapy after any breast surgery for stage 1-3 invasive breast cancer, tumor >1 cm, and estrogen receptor-negative, applying
only to patients aged <70 years (NQF 0559; NCCN 3.2013, BINV-8)
Metric 3 Mammogram every 12 mo for 5 y after the first breast-conserving surgery (NCCN 3.2013, BINV-16)
Colon cancer
Metric 1 Colectomy with lymphadenectomy for stage 1-3 (resectable cancer; NCCN 3.2013, COL-2)
Metric 2a Adjuvant chemotherapy for Stage 3 colon cancer (NQF, 0385; NCCN 3.2013, COL-4)
Metric 2b Initiation of adjuvant chemotherapy within 3 mo of surgery date (NQF, 0223; for patients aged <80 y)
Metric 3 Colonoscopy within 12 mo after resection for stage I-III cancer (NCCN 3.2013, COL-3 and COL-4)
Prostate cancer
Metric 1 Primary therapies are prostatectomy, EBRT, brachytherapy (alone or combined with EBRT), and active surveillance
Metric 1a Stage 1-2, low grade (SEER grade 1 [well differentiated]): Active surveillance, surgery, EBRT, brachytherapy (NCCN 4.2013, PROS-2)
Metric 1b Stage 1-2, intermediate grade (SEER grade 2 [moderately differentiated]): Surgery, EBRT, EBRT plus brachytherapy, EBRT plus ADT, EBRT with
brachytherapy plus ADT (NCCN 4.2013, PROS-3)
Metric 1c Stage 1-2, high grade: Surgery, EBRT plus ADT, EBRT with brachytherapy plus ADT (NCCN 4.2013, PROS-4)
Metric 1d Stage 3, any grade: Surgery, EBRT plus ADT, EBRT with brachytherapy plus ADT (NCCN 4.2013, PROS-4)
Metric 2 Any ADT or primary EBRT for high-grade tumors (SEER grade 3 and 4 [poorly differentiated, or undifferentiated, or anaplastic), during/near RT
(NCCN 4.2013, PROS-4)
Metric 3 At least 1 PSA every 12 mo for 5 y after the first primary treatment (surgeries, or EBRT, or brachytherapy) or after the first active surveillance
period (from diagnosis to 12 mo) if no treatment (NCCN 4.2013, PROS-5)
Lung cancer
Metric 1a Nonsmall cell lung cancer stage 1-2: Surgery (lobectomy with mediastinal lymph node dissection; NCCN 2.2013, NSCL-3; NCI PDQ)
Metric 1b Nonsmall cell lung cancer stage 3a: Neoadjuvant chemoradiation therapy followed by surgery (lobectomy plus mediastinal lymph node
dissection; NCCN 2.2013, NSCL-7)
Metric 1c Small cell lung cancer: No role for surgery; stage 3 other than 3a (such as stages 3b, 3c, 3 NOS, . . .): no role for surgery (NCCN 1.2014,
SCL-A)
Metric 2a No adjuvant therapy role for stage 1 disease (NCI PDQ)
Metric 2b Adjuvant chemotherapy or RT for nonsmall cell lung cancer stage 2 (NCCN 2.2013, NSCL-3)
Metric 2c Adjuvant RT for nonsmall cell lung cancer stage 3a (NCCN 2.2013, NSCL-3)
Metric 3 Surveillance starts from 2 mo after completion of first treatment (treatments include surgeries for patients who undergo surgeries or first
chemotherapy or RT for chemoradiation-only patients); the surveillance will be CT scans of the chest every 12 mo for 5 y (NCCN 2.2013,
NSCL-13)
Abbreviations: ADT, androgen-deprivation therapy; BINV, NCCN invasive breast cancer guideline; CT, computed tomography; EBRT, external-beam radiation
therapy; NCCN 2.2013, NCCN guidelines, version 2.2013; NCCN 4.2013, NCCN guidelines, version 4.2013; NCI PDQ, National Cancer Institute Physician Data
Query; NOS, not otherwise specified; NQF, National Quality Forum; NSCL, NCCN nonsmall cell lung cancer guideline; PROS, NCCN prostate cancer guideline;
PSA, prostate-specific antigen; SCL, NCCN small cell lung cancer guideline; SEER, Surveillance, Epidemiology, and End Results Program.
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data for this study. Individuals are classified as AI/AN if
they have a reservation residence, if they have evidence of
medical coverage through the IHS, or if their medical re-
cord indicates AI/AN race. Data collected in the registries
include patient demographics, primary tumor site, stage
at diagnosis, first course of treatment, and follow-up for
vital status. For those aged65 years, 97% are eligible for
Medicare, and 93% of patients in the SEER files are
matched to the Medicare enrollment file.8 This study
included all Medicare-eligible patients with incident cases
in the SEER database from 1996 through 2005 andMedi-
care claims follow-up through 2007.
Patient Eligibility
Patients were included in this study if they were diagnosed
with 1 of the following 4 primary cancers: breast, colon,
lung, or prostate. In total, 1032,605 patients were identi-
fied with these incident cancer diagnoses. Patients were
excluded for the following reasons: cancer diagnosed
before age 65 years or before the year 1996
(n5 267,423), in situ disease (Tis) or metastatic disease
(TxNxM1) at diagnosis (n5 268,453), and information
abstracted from autopsy/death certificates or nursing/hos-
pice records (n5 28,881). To ensure complete claims
data, we required continuous enrollment in both Medi-
care Parts A and B with no health maintenance organiza-
tion coverage during the study period defined for each
metric (excluded, n5 120,830). Charlson comorbidity
index (CCI) scores were calculated using the methods out-
lined by Deyo et al.9 After exclusion criteria were applied,
there were 338,204 patients who formed our study
cohort. After diagnosis, patients were followed until death
or until the last date for which Medicare claims data were
available.
Defining Optimal Care
We selected nationally recognized, cancer-specific guide-
lines that address surgical therapy, adjuvant therapy, and
post-treatment surveillance as metrics for defining opti-
mal care for breast, lung, prostate, and colon cancer. Each
was selected on the basis of it being a recommendation in
the NCCN Clinical Practice Guidelines in Oncology
categorized as either level 1(high-level evidence with uni-
form expert consensus), level 2a (lower level evidence with
uniform expert consensus), level 2b (lower level evidence
with expert consensus), or a guideline of the NCI or
NQF. These 22 measures and their referenced sources are
detailed in Table 1: Metric 1 includes surgical guidelines,
Metric 2 includes adjuvant therapy guidelines, andMetric
3 includes post-therapy surveillance guidelines. Flow dia-
grams detailing the exclusionary and inclusionary criteria
for each metric are presented elsewhere (see the online
supporting information). Current (as opposed to historic)
guidelines were used because they were publicly and read-
ily available. In addition, all of the NCCN guidelines we
selected for study, with the exception of androgen-
deprivation therapy for prostate cancer, mirrored NCCN
treatment guidelines published during the years of our
study. Medicare claims codes, including International
Classification of Diseases ninth edition (ICD-9), Current
Procedure Terminology (CPT), and SEER codes, are pro-
vided in the online supporting information.
Unadjusted rates for the receipt of surgical and adju-
vant therapies (Metrics 1 and 2) were calculated as the
proportion of patients that received a therapy among
those who were eligible. The rate for cancer surveillance
(Metric 3) was calculated for each patient as the ratio of
the number of surveilled 12-month post-therapy periods
(defined as receipt of at least 1 screening test during the
12-month period post-therapy) divided by the number of
12-month post-therapy periods available for analysis.
Analyses ended as soon as 1 of the following events
occurred: the date of death; the follow-up cutoff date of
December 31, 2006; or at 5 years postoperatively.
Statistical Analysis
A direct comparison of optimal care receipt by AI/ANs
and whites was not appropriate because of the extremely
unbalanced sizes of the groups (eg, colon cancer: 194 AI/
ANs vs 55,268 whites). Because of this imbalance and to
mitigate the confounding effects of the demographic and
clinical differences between AI/ANs and whites, as pre-
sented in Table 2, we developed a cohort of white patients
who were matched to AI/AN patients based on sex, age at
diagnosis, CCI, SEER registry geographic site, diagnosis
year, and cancer stage at diagnosis. A random sample of
matched whites was then drawn at a ratio of 10:1 for each
matching pair with AI/ANs. When comparing sampled
whites with AI/ANs, the chi-square test was used to test
the significance of associations between race and categori-
cal metric outcomes, and the Student t test was used to
evaluate associations between race and continuous metric
outcomes. To reduce bias because of the results from a
single random sample, a subsampling method (m of n
without replacement bootstrap) was applied.10,11 One
thousand iterations (resampling plus testing) were run for
each cancer metric. P values presented in Table 3 were the
optimal results summarized from all iterations.10 To com-
pare the likelihood of receiving optimal care by race using
adjusted odds ratios, we conducted standard multivariate
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logistic regression modeling for Metrics 1 and 2 on the
cohort of AI/ANs and matched whites. Covariates
adjusted for in our analyses included race, age, SEER
registry site/geographic region, diagnosis year, cancer
stage, and CCI.
To analyze the association between receipt of opti-
mal care and cancer-specific survival, and because of the
nonproportional hazards indication by the Schoenfeld
residuals12 of Metric1 for all 4 cancers and Metric2 for
breast cancer and colon cancer, we performed the
extended Cox regression modeling, which could incorpo-
rate the time-dependent covariates and allowed nonpro-
portional hazards.12,13 Patients who died from other
causes were excluded. Survival was calculated from the
date of diagnosis to the date of either death or last follow-
up. Metrics 1 and 2 were set as the time-dependent covari-
ates in their corresponding extended Cox models, because
their values changed over the course of observation after
the diagnosis date. The models were fitted on the entire
unmatched cohort, and the estimates of the overall
adjusted hazard ratios associated with receipt of Metrics
1 and 2 were obtained.13,14 The models adjusted for age
at diagnosis, race, diagnosis year, cancer stage, CCI, and
SEER registry site.
Because analyses comparing AI/ANs and whites
were based on stringent matching criteria with resultant
TABLE 2. Cohort Demographics and Diagnoses
Age at Diagnosis, %
Disease
Stage, %
CCI Score 6 Mo
Before Diagnosis, %
Race
Sample Size:
No. (%) Women, % 65-69 Y 70-74 Y 75-79 Y 80 Years I II III 0 1 2
Breast cancer
AI/AN 216 (0.24) 100 25.9 25.9 24.1 24.1 50.9 39.8 9.3 61.5 23.5 15
White 76,185 (86.1) 99.1 23.1 24.1 23.9 29 57.2 35.8 7 74.5 18.3 7.2
Colon cancer
AI/AN 211 (0.3) 61.6 22.8 27.5 20.9 28.9 25.6 42.2 32.2 53.1 26.6 20.3
White 58,318 (83) 55.2 16.3 20.4 23.5 39.8 30.2 40.4 29.4 57 26.8 16.2
Prostate cancer
AI/AN 279 (0.27) 0 42.3 26.5 20.4 10.8 40.1 44.1 15.8 68.4 20.5 11.1
White 80,654 (78.1) 0 31.5 30.2 22.8 15.5 48.3 41.5 10.2 76.7 16.4 6.9
Lung cancer
AI/AN 211 (0.28) 44.1 29.4 24.6 23.7 22.3 36 9.5 54.5 33 39.6 27.4
White 64,240 (84.4) 48 23.5 26.7 25.3 24.6 41.2 6.7 52.1 40.4 37.3 22.4
Abbreviations: AI/AN, American Indian/Alaskan Native; CCI, Charlson comorbidity index.
TABLE 3. Adjusted Associations of Optimal Care Measures With Race
Metric 1: Surgery/Primary Care Metric 2: Adjuvant Therapy Metric 3: Post-Therapy Surveillance
Matched Cohort Matched Cohort Matched Cohort
Race No. Treatment Rate,% Pa No. Treatment Rate,% Pa No. Treatment Rate,% Pa
Breast cancer
AI/AN 206 79.1 .010 102 61.8 < .001 92 64 .002
White 8052 85.7 5038 82.2 4647 76.4
Colon cancer
AI/AN 194 87.1 .002 42 45.2 .001 164 55.5 .341
White 2012 94.2 306 72.9 1875 57.1
Prostate cancerb
AI/AN 250 39.2 <.001 NAc 10.4 .756 213 57.8 <.001
White 11,119 60 1264 12.1 10,131 81.4
Lung cancer
AI/AN 95 26.3 .025 NAc 41.7 .576 129 49.6 .223
White 1128 40 132 30.3 1735 55
Abbreviations: AI/AN, American Indian/Alaskan Native; NA, not available.
aP values were based on 1000 bootstrapping iterations.
bNo sex variable was used for prostate cancer.
c Information in this cell is masked to comply with privacy regulations.
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smaller white populations, we conducted a sensitivity
analysis using a less stringent matching strategy (broader
categorization by SEER geographic region vs individual
registry site and broader categories of diagnosis years). In
this way, we expanded the matched white population to
ensure that our comparisons remained valid. All analyses
in this study were conducted using the statistical software
package SAS 9.3 (SAS Institute Inc., Cary, NC).
RESULTS
Demographic and Clinical Characteristics
Demographics
Across all 4 cancers, fewer AI/ANs presented with stage I
disease and higher percentages presented with locally
advanced, or stage III, disease compared with white
patients (Table 2). In addition, AI/AN patients tended to
present at younger ages (eg 22.8% of AI/ANs vs 16.3% of
whites were diagnosed with colon cancer at ages 65-69
years). AI/AN patients also tended to have a greater bur-
den of comorbid disease, reflected by a higher CCI at the
time of diagnosis.
Receipt of optimal care
Across the entire unmatched cohort, AI/ANs were less
likely than whites to receive primary surgical therapy or to
undergo recommended post-therapy surveillance across
all cancer types (data not shown). AI/AN patients were
also less likely than whites to receive adjuvant chemother-
apy or radiation therapy for breast, colon, or prostate can-
cer. However, AI/ANs appeared to be more likely to
receive adjuvant therapy for lung cancer.
In adjusted analyses across all 4 cancers, AI/AN
patients were significantly less likely than white patients
to receive guideline-concordant care (Table 3). AI/AN
patients were consistently less likely to undergo curative
surgical resection (P .025 for all cancers) and were less
likely to receive recommended adjuvant therapies for
breast cancer (P< .001) and colon cancer (P5 .001). AI/
AN patients had 37% to 58% lower odds of undergoing
surgery (Fig. 1), a disparity that was significant across can-
cer types. AI/AN patients also had 53% and 64% lower
odds of receiving adjuvant therapy for breast cancer (odds
ratio [OR], 0.47; 95% confidence interval [CI], 0.29-
0.76) and colon cancer (OR, 0.36; 95%CI, 0.19-0.70),
respectively. The rates at which patients received adjuvant
therapy for prostate and lung cancer did not differ signifi-
cantly, which may be attributable to the very small popu-
lation eligible for this metric. Rates of post-therapy
surveillance also were lower among AI/AN patients across
cancer types, although the difference was significant only
for breast cancer (P5 .002) and prostate cancer
(P< .001). Similar significant results were obtained from
our sensitivity analysis.
Survival and Receipt of Optimal Care
The median follow-up was 41 to 58months for breast, co-
lon, and prostate cancers and 14 months for lung cancer.
Race was not significantly associated with survival once
other demographic and disease variables were controlled
for. Therefore, hazard ratios (HRs) for cancer-specific sur-
vival associated with nonreceipt of Metrics 1 and 2 were
calculated using the entire cohort of AI/ANs and
(unmatched/all) whites combined (Fig. 2). The overall
likelihood of survival was 38%, 26%, 48%, and 64%
lower among the patients who did not receive Metric 1
therapy for breast, colon, prostate, and lung cancer,
respectively, compared with those who did undergo sur-
gery (upper 95% CI, all <1.0). The overall likelihood of
survival also was significantly lower for the patients with
breast cancer (HR, 0.56; 95% CI, 0.53-0.59), colon can-
cer (HR, 0.59; 95% CI, 0.56-0.64), and prostate cancer
(HR, 0.81; 95% CI, 0.71-0.91) who did not receive Met-
ric 2 therapy. No significant association was observed
between receipt of adjuvant therapy and lung cancer
survival.
Next, we assessed whether the interaction between
race and optimal care had an important impact on the
likelihood of survival for Metrics 1 (surgery) and 2 (adju-
vant therapy) in the matched cohort. The interaction
Figure 1. The likelihood of receiving optimal care among
American Indians/Alaskan Natives (AI/ANs) compared with
whites is illustrated. Multivariate logistic regression modeling
is shown for Metric 1 (surgery/primary care) and Metric 2 (ad-
juvant therapy) for each cancer. Covariates included race;
age at diagnosis; Surveillance, Epidemiology, and End Results
registry site; year of diagnosis; cancer stage; and Charlson
comorbidity index. LCL indicates lower control limit; UCL,
upper control limit.
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coefficient was not significant at the test criterion a5 .05
level, which indicates that AI/ANs and whites have a simi-
lar likelihood of survival after controlling for receipt of
treatment, demographics, and disease features.
DISCUSSION
Ours is the first study to explore lower survival rates
among AI/AN patients with cancer by assessing whether
disparities exist in the receipt of guideline-concordant
cancer treatment. We observed that AI/AN patients were
less likely to receive optimal, guideline-concordant care
compared with whites. Rates of primary surgical therapy
for the 4 most common cancers (breast, colon, prostate,
and lung) were significantly lower among AI/ANs com-
pared with matched white patients. Rates of adjuvant
therapy also were lower among AI/AN patients with
breast cancer and colon cancer. Given the very small sam-
ple size of patients evaluable for receipt of adjuvant ther-
apy for prostate cancer and lung cancer, the lack of
significant differences between racial groups is not surpris-
ing. Surveillance test rates after treatment for breast or
prostate cancer (ie, screening mammogram, prostate-
specific antigen) among AI/ANs lagged far behind whites.
However, rates of surveillance with screening colonoscopy
after colon cancer treatment were low across racial groups.
The entire AI/AN population comprises only about
1.7% of the US population, making it a challenge to con-
duct rigorous studies of either processes or outcomes of
care among AI/ANs, particularly using single data sets.15
The NCI-funded SEER registry includes data on 42% of
AI/ANs living in the United States. Prior studies of dis-
parities in cancer treatment have been limited by AI/AN
race misclassification and small sample size. Conse-
quently, to date, AI/ANs have been categorized broadly in
the context of “other” minorities, and data specific to AI/
ANs are scarce. To mitigate the problem of race misclassi-
fication, the IHS, NCI, Centers for Disease Control and
Prevention, and all SEER registries collaborated in 1999
to link IHS beneficiary records with cancer registry data-
bases, which has led to a greatly improved process for
identifying AI/AN race in the SEER registry.7,16-19
Among racial groups, AI/ANs have the lowest sur-
vival rates for cancers of the breast, lung, and prostate and
for all cancers combined.20 Higher cancer mortality rates
among AI/AN patients may relate to a more advanced
stage of cancer at presentation, which we observed in this
study. An earlier study by Espey et al also demonstrated
that AI/ANs present with more advanced stages of cancer
compared with white patients who have breast, prostate,
and colon cancers.2 A more advanced stage of cancer at di-
agnosis and reduced rates of surgical resection and chemo-
therapy have been linked to survival disparities among
black and Hispanic patients with lung and colorectal can-
cers.21-23 Another SEER-based study conducted between
1988 and 2006 indicated that AI/ANs with stage I
through III nonsmall cell lung cancer had rates of surgical
resection that were significantly lower than the rates
among whites.24 In addition, 5-year lung cancer-specific
survival was 47% for AI/ANs versus 56% for whites
(P< .0001). Not surprisingly, we demonstrated that sur-
vival was lower among those patients with cancer who did
not receive guideline-concordant therapy. Importantly,
we demonstrated that if optimal treatment was received,
and disease stage and demographics controlled for, dis-
ease-specific survival of AI/ANs and whites did not signifi-
cantly differ.
Potential etiologies for lower rates of guideline-
concordant cancer therapy and surveillance among AI/
ANs likely include systems-based, provider-based, and
patient-based factors. A larger percentage of AI/ANs
(42% vs 23% whites) reside in rural areas with presum-
ably lesser access to cancer specialists.15 The IHS hospitals
and clinics are based on reservations and provide care to
approximately 1.6 of the 4 million individuals in the
United States who identify themselves as Native Ameri-
can.25,26 However, even for individuals who are eligible
for the IHS, access to specialty care is limited. Cancer care
is provided through Contract Health Services, because the
Figure 2. The association between receipt of optimal care
and survival is illustrated. Cox proportional hazards regres-
sion modeling was used to estimate the adjusted hazard
ratios associated with receipt of Metric 1 (surgery/primary
care) and Metric 2 (adjuvant therapy). The models were
adjusted for race; age at diagnosis; Surveillance, Epidemiol-
ogy, and End Results registry site; year of diagnosis; cancer
stage; and Charlson Comorbidity Index. LCL indicates lower
control limit; UCL, upper control limit.
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IHS does not employ any oncologists.27 Specialist refer-
rals made through the Contract Health Services depend
on sufficient funding from Congress, which introduces
additional potential delays in or barriers to care. The dis-
parity we observed in receipt of optimal care cannot be
explained by variance in insurance coverage, because all
patients who were included in our study population had
complete Medicare coverage.
Cultural factors also may play a role in lower rates of
receipt of cancer treatments, because some AI/ANs may
place greater trust in nontraditional health care providers.
Others have reported that mistrust of the health care sys-
tem and providers contributes to observed disparities in
the treatment of AI/ANs.28,29 A novel survey study evalu-
ating the beliefs of AIs and whites about cancer treatment
revealed that AIs are significantly more likely to hold neg-
ative perceptions of how cancer treatment will affect
them.29 For instance, 38% of AIs versus 1% of whites
believed that cancer treatments always cause a patient’s
hair to fall out. Twenty-nine percent of AIs versus 1% of
whites believed that cancer treatments always make indi-
viduals so sick that they are unable to go on about their
daily lives. Such misconceptions of the impact of cancer
therapy on daily life may play a large role in AI patients’
reluctance to agree to standard therapies. Culturally
focused education programs at the community level to
inform AI/AN patients about such therapies could poten-
tially increase their acceptance. Such an educational inter-
vention targeted toward AI women succeeded in
increasing rates of mammographic screening for breast
cancer.30 Currently, the CINCO group is working within
AI/AN communities to conduct key informant interviews
and patient-provider dyad surveys that will elucidate the
barriers to receiving cancer treatment and will provide
appropriate and collaborative targets for intervention.
Our study had limitations that should be noted. First,
definitions of optimal cancer care were based on current
disease-specific clinical practice guidelines and could yield
biased results, particularly for those guidelines that were
modified in the later years of the study. To mitigate this,
we intentionally selected less controversial, longstanding
treatment guidelines. Upon review of archived 1996, 2000,
and 2005 NCCN guidelines attained with NCCN permis-
sion, all of our selected NCCN breast, lung, and colon can-
cer metrics were similar to historic NCCN guidelines from
the study period. The only significant variation was in the
prostate cancer guidelines, which introduced a recommen-
dation of adjuvant androgen-deprivation therapy for inter-
mediate grade stage 1 and 2 prostate cancer subsequent to
2005. Because patients were concordant for this metric
(Metric 1b) whether or not they received androgen-
deprivation therapy, this variation in the guideline should
not have had an impact on our results. For Metric 2 (breast
cancer adjuvant therapy), the NCCN guideline for radia-
tion therapy after breast-conserving surgery has changed in
recent years to apply only to those patients aged <70 years
who have estrogen receptor-positive cancers and are receiv-
ing tamoxifen. We performed an additional analysis exam-
ining rates of receipt of Metric 2 adjuvant therapy
restricted to patients aged <70 years and observed that the
significant disparity between AI/ANs (n5 30) and
matched whites (n5 1633) persisted (P5 .033). Given
the small number of AI/AN patients to which this subset
analysis was restricted, we opted to present the larger popu-
lation of AI/ANs unrestricted by age, as indicated in Table
3. In addition, because we were interested in a comparison
between AI/ANs and whites with regard to the receipt of
optimal care, as opposed to the primary rates of concord-
ance within each racial category, we did not believe it was
necessary to adjust guidelines by individual year. In addi-
tion, we controlled for year of diagnosis in our multivariate
analysis. Second, the SEER AI/AN population is largely
comprised of AI/ANs in the West (New Mexico, Pacific
Northwest, and California) and may not be generalizable
to all AI/ANs in the United States. Third, the population
size of AI/ANs in the SEER-Medicare data is still small,
approaching only 0.3% that of whites and resulting in chal-
lenges to meaningful comparison for some quality metrics.
However, the SEER-Medicare data set still provides 1 of
the most robust tools publicly available to study AI/ANs.2
In summary, we demonstrated that AI/AN patients
are less likely to receive guideline-concordant, or optimal,
surgical and adjuvant therapy and post-therapy surveillance
compared with white patients. In addition, nonreceipt of
guideline-concordant cancer care was associated with worse
cancer-specific survival for AI/ANs and whites alike. In
light of these pervasive disparities and our confirmation
that receipt of optimal cancer treatments is associated with
improved cancer survival, efforts should be made to address
root causes. In the CINCO group, we are currently exam-
ining both more distal or systems-related and access-related
issues as well as more proximal, community-based and
individual-based factors to clarify which interventions
could most effectively target such disparities.
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